Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Biol Ther. 2014 May;15(5):483-5. doi: 10.4161/cbt.28160. Epub 2014 Feb 20.

Tumor cells and memory T cells converge at glycolysis: therapeutic implications.

Author information

1
Department of Radiology & Radiological Sciences; Johns Hopkins University School of Medicine; Baltimore, MD USA.

Abstract

In the immune system, activation of naïve T (Tn) cells into effector T cells (Teff) involves a metabolic switch to glycolysis to promote rapid proliferation and differentiation. In the October issue of The Journal of Clinical Investigation, Sukumar et al. have demonstrated that in CD8(+) memory T (Tems) cells glycolytic phenotype contributes to the shortened lifespan of Tems. Conversely, inhibition of glycolysis in Tems not only extended their viability but also augmented desirable properties. Notably, they also demonstrate that glycolytic inhibition during the ex vivo clonal expansion of tumor-specific Tems enhanced their antitumor function. Overall, the data suggest that an antiglycolytic strategy targeting the Tems could enhance antitumor immune response. On the other hand, cancer cells have long been known to exhibit metabolic reprogramming which involves a shift toward glycolysis (the conversion of glucose into lactate) to facilitate uninterrupted growth. Interestingly, antiglycolytic treatment of cancer cells has been known to trigger antitumor immune response as well. Taken together, it is probable that a strategy involving concurrent inhibition of glycolysis in tumor cells and Tems could promote a dual attack on cancer by inducing an effective antitumor immune response and an immunogenic chemotherapy.

KEYWORDS:

T cells; cancer; chemotherapy; glycolysis; immunotherapy

PMID:
24556820
PMCID:
PMC4026068
DOI:
10.4161/cbt.28160
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center